Semaglutide and Cardiovascular Outcomes in Obesity Without Diabetes (SELECT)

glp1 · New England Journal of Medicine · 2023

Semaglutide 2.4mg cut major cardiovascular events by 20% in overweight/obese adults without diabetes over ~40 months.

Authors

Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.

Semaglutide 2.4mg cut major cardiovascular events by 20% in overweight/obese adults without diabetes over ~40 months.